---
title: "Pharmacology Clinical Research Feed | MedicHelpline"
specialty: "Pharmacology"
specialty_slug: "pharmacology"
canonical_url: "https://medichelpline.com/clinical-feed/pharmacology"
content_type: "clinical_feed_specialty"
page: 1
articles_in_batch: 30
generated_at: "2026-09-05T23:52:37.113Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pharmacology — Clinical Research Feed
## Specialty Overview: Pharmacology
Latest peer-reviewed clinical trials, guidelines, and observational research in **Pharmacology**, indexed and structured for clinical intelligence and AI reasoning.
## Latest Pharmacology Publications
### 1. [AA147 and Metabolically Activated Proteostasis Regulators Suppress CD4+ TH17 Differentiation](https://medichelpline.com/clinical-feed/biorxiv-0-metabolically-activated-proteostasis-regulators-reduce-differentiation-of-cd4.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-05
- **Detail Markdown URL:** [AA147 and Metabolically Activated Proteostasis Regulators Suppress CD4+ TH17 Differentiation](https://medichelpline.com/clinical-feed/biorxiv-0-metabolically-activated-proteostasis-regulators-reduce-differentiation-of-cd4.md)

> **Executive GIST:** - The study reports that the metabolically activated proteostasis regulator **AA147** selectively reduces differentiation of pro-inflammatory **TH17** cells from naive CD4+ T cells. - AA147 was previously identified as a compound that can activate the ATF6 arm of the unfolded protein response (UPR) and, in some cell types, the **NRF2**-mediated oxidative stress response (OSR). - In this work, AA147 promotes degradation of the lineage-specifying transcription factor **RORgammat**, a key driver of TH17 identity, thereby reducing TH17 differentiation without altering transcription factors of other CD4+ T cell subsets. - The reduction of TH17 differentiation by AA147 is independent of **ATF6** activation and instead involves activation of **NRF2**, which lowers intracellular reactive oxygen species (**ROS**) levels to impede TH17 cell development. - AA147 also decreases expression of the TCR-responsive factor **IRF4**, which contributes to suppressed production of selected effector cytokines across effector T cell subsets, indicating broader dampening of effector cytokine responses. - The compound reshapes T cell subset activities via both **NRF2-dependent** and NRF2-independent mechanisms during differentiation. - The findings suggest pharmacologic targeting of stress-responsive pathways as a means to selectively remodel T cell subset differentiation, with AA147 as a candidate metabolically activated proteostasis regulator for modulating TH17 identity and effector responses. - The article is a preprint and has not been peer reviewed. A competing interest is declared: RLW is a shareholder and advisory board member of a company that has licensed proteostasis regulators including AA147; other authors report no conflicts.

### 2. [Lacosamide Adsorption to Dialysis Membranes During CRRT: Effects on Drug Dosing](https://medichelpline.com/clinical-feed/pubmed-42698197.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.12659/MSM.952323](https://doi.org/10.12659%2FMSM.952323)
- **Detail Markdown URL:** [Lacosamide Adsorption to Dialysis Membranes During CRRT: Effects on Drug Dosing](https://medichelpline.com/clinical-feed/pubmed-42698197.md)

> **Executive GIST:** - In vitro study evaluated **lacosamide** adsorption to three dialysis filter membranes (polysulfone **PS**, polyacrylonitrile **PAN**, and polyacrylonitrile polyethyleneimine **PAN-PEI**) and assessed drug stability in saline and plasma solutions. - Lacosamide at 200 µg/mL was prepared in 0.9% NaCl and bovine plasma, perfused through each filter, and samples collected up to 90 minutes for HPLC measurement. - Chemical stability: lacosamide concentrations in saline and plasma varied by less than 7% over 90 minutes, indicating **stability** in both matrices. - In 0.9% NaCl, measurable **adsorption** occurred with concentration reductions at 90 minutes of 33.52% (PS), 20.71% (PAN), and 14.73% (PAN-PEI). - In plasma, adsorption differed: PS showed 17.96% reduction, PAN-PEI 23.04%, and PAN 27.71% at 90 minutes. - Statistical testing found no significant differences in adsorption among the three membrane types (P > 0.05). - Overall, adsorption was more pronounced in plasma than saline for PAN and PAN-PEI membranes; PS showed greater adsorption in saline than plasma. - Clinical implication: measurable lacosamide loss on dialysis membranes suggests potential decreases in circulating drug concentrations during extracorporeal circulation; consideration is warranted when dosing lacosamide during hemodialysis or continuous renal replacement therapy (**CRRT**) in critically ill renal patients. - Methodological note: study was in vitro using bovine plasma and specific membrane types; direct extrapolation to all clinical CRRT settings or patient outcomes is not provided in the source.

### 3. [Liposuction versus conservative therapy for lipoedema: multicentre randomised trial in Germany](https://medichelpline.com/clinical-feed/pubmed-42692034.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/S0140-6736(26)00910-4](https://doi.org/10.1016%2FS0140-6736(26)00910-4)
- **Detail Markdown URL:** [Liposuction versus conservative therapy for lipoedema: multicentre randomised trial in Germany](https://medichelpline.com/clinical-feed/pubmed-42692034.md)

> **Executive GIST:** - This is a multicentre, **randomised controlled trial** comparing **liposuction** with conservative therapy for patients with **lipoedema** conducted in Germany and published in Lancet. - Publication details: Lancet. 2026 Sep 5;408(10558):910-923. DOI 10.1016/S0140-6736(26)00910-4. PubMed PMID 42692034. - The trial is described in the PubMed record with a full author list led by Maurizio Podda and includes multiple investigators and clinical sites across Germany. - Participating authors and institutions include departments of dermatology, plastic and reconstructive surgery, clinical trials centre and medical statistics groups at multiple German centres (Darmstadt, Bad Belzig, Düsseldorf, Cologne, Bonn, Potsdam, and others). - The PubMed entry classifies the work as a Randomized Controlled Trial and shows it appeared in a high-impact general medical journal. - The PubMed page excerpt available here lists authors, affiliations, citation, PMID and DOI but does not include the abstract text, trial methods, primary or secondary endpoints, sample size, numerical results, safety data, or conclusions in the provided content. - Specific trial details (eligibility criteria, randomisation method, interventions, follow-up duration, outcome measures, statistical analysis, results, and interpretation) were not reported in the source excerpt and therefore cannot be summarised from this source alone. - For complete study protocol, methods, results and clinical conclusions, consult the Lancet full text (DOI provided) or the PubMed record external links for the full abstract and article text.

### 4. [Adverse Pregnancy Outcomes as Predictors of Long-Term Cardiovascular Disease Risk](https://medichelpline.com/clinical-feed/pubmed-42669304.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/S0140-6736(26)01235-3](https://doi.org/10.1016%2FS0140-6736(26)01235-3)
- **Detail Markdown URL:** [Adverse Pregnancy Outcomes as Predictors of Long-Term Cardiovascular Disease Risk](https://medichelpline.com/clinical-feed/pubmed-42669304.md)

> **Executive GIST:** - Pregnancy functions as a physiological stress test that can reveal latent cardiovascular vulnerability; **adverse pregnancy outcomes** (APOs) are markers of higher long-term cardiovascular morbidity and mortality. - Common APOs discussed include **hypertensive disorders of pregnancy (HDP)**, **gestational diabetes**, and **preterm birth** (delivery before 37 weeks' gestation); each is associated with substantially increased long-term cardiovascular risk compared with women without APOs. - The observed excess cardiovascular risk likely reflects a mix of pre-existing cardiometabolic and genetic susceptibility plus pregnancy-related haemodynamic and metabolic stressors that accelerate risk factor trajectories and impair endothelial and microvascular function. - The Review synthesises epidemiological data across major APO phenotypes and highlights emerging evidence that maternal APO history is linked to adverse cardiometabolic trajectories in offspring. - Proposed mechanistic pathways include unmasked pre-existing risk, pregnancy-triggered acceleration of cardiometabolic disease processes, and persistent vascular and metabolic dysfunction after delivery. - Current guidance and consensus-informed recommendations for short-term and long-term follow-up after APOs are summarised, and practical approaches for integrating APO history into cardiovascular risk assessment are proposed. - Key knowledge gaps are identified: uncertainty about optimal follow-up models, limitations of existing risk-stratification tools to account for APOs, and the absence of APO-specific prevention trials. - The authors prioritise mechanistic and implementation research and position APOs as early, sex-specific indicators offering an upstream prevention opportunity to improve cardiovascular outcomes for women.

### 5. [Ultrasonic detection of irreversible moisture effects on tablet microstructure and micro-viscoelas](https://medichelpline.com/clinical-feed/pubmed-42567374.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127277](https://doi.org/10.1016%2Fj.ijpharm.2026.127277)
- **Detail Markdown URL:** [Ultrasonic detection of irreversible moisture effects on tablet microstructure and micro-viscoelas](https://medichelpline.com/clinical-feed/pubmed-42567374.md)

> **Executive GIST:** - Moisture exposure by uniform vapor diffusion (no direct liquid contact) increased tablet mass by about **8.3 ± 0.77%**, demonstrating uptake without surface wetting. - A controlled dry-down following moisture exposure allowed serial ultrasonic acquisition using a custom pitch‑catch rig with paired pressure transducers. - Waveforms were analyzed in the temporal, spectral, and wave‑dispersion domains to extract both bulk- and microstructure-sensitive metrics. - Geometric recovery after drying was minimal: diameter, thickness, and mass density increased by approximately **0.97 ± 0.25%**, **1.83 ± 0.13%**, and **3.69 ± 0.49%**, respectively, relative to the initial dry state. - In contrast, substantial irreversible reductions were measured in ultrasonic-derived mechanical metrics: pressure wave speed (~**28.87%** reduction), group velocity (~**13.20%** reduction), and apparent modulus of elasticity (~**47.34%** reduction). - Residual stress assessment showed equivalent axial residual stress remained roughly **3–4 times** higher than equivalent radial residual stress after drying, indicating anisotropic, non-uniform recovery. - Findings indicate that **ultrasonic characterization** is a sensitive, non-destructive method to detect irreversible moisture-induced microstructural and micro-viscoelastic changes that are not apparent from gross geometric measurements. - The study frames ultrasonic assessment as a potential **Process Analytical Technology (PAT)** and quality-assurance tool relevant to **Continuous Manufacturing (CM)**, Critical Quality Attributes (CQA), Quality by Design (QbD), and real-time release testing (RTRT).

### 6. [Quject® lyotropic liquid crystal gel for long-acting ropivacaine: structure, PK, and sustained ana](https://medichelpline.com/clinical-feed/pubmed-42562133.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127284](https://doi.org/10.1016%2Fj.ijpharm.2026.127284)
- **Detail Markdown URL:** [Quject® lyotropic liquid crystal gel for long-acting ropivacaine: structure, PK, and sustained ana](https://medichelpline.com/clinical-feed/pubmed-42562133.md)

> **Executive GIST:** - The study reports a bioresponsive **Quject® gel** — a lyotropic liquid crystal system based on lecithin, Span 20, and tocopherol acetate — optimized to undergo an in situ sol–gel transition when exposed to biological fluids. - Structural analyses (SAXS and cryo-TEM) confirmed formation of a stable **reversed hexagonal phase** with a lattice constant of approximately 5.80 nm and characteristic Bragg peaks at q ≈ 0.80, 1.38, and 1.60 nm⁻1 (1:√3:√4 ratio). - The dense nanochannels of the hexagonal depot restricted **ropivacaine** diffusion, producing a low initial burst (Day-0: 3.80%) and sustained release (43.66% cumulative release by Day-7) versus lamellar controls that released ≥95% over the same period. - In vivo rat pharmacokinetics showed prolonged systemic exposure: elimination half-life increased sevenfold (t1/2: 5.98 vs. 0.81 h) and peak plasma concentration decreased fourfold (Cmax: 58.13 vs. 231.00 ng/mL) compared with ropivacaine HCl. - The formulation extended measurable drug concentration to tlast = 42 h, covering much of the critical 48-h postoperative window while reducing peak systemic levels associated with toxicity risk. - Functional efficacy in a rat incision model (von Frey testing) demonstrated sustained **analgesic** effect up to 72 h after a single subcutaneous dose, compared with ≤6 h for ropivacaine HCl. - The authors conclude a direct structure–pharmacokinetics–efficacy relationship for the Quject® gel, suggesting a scalable, biocompatible approach for prolonged postoperative analgesia. - Keywords highlighted by the source: In situ sol–gel transition; Long-acting injectable; **Lyotropic liquid crystal**; Postoperative pain management.

### 7. [Chloroquine–resin complexes: formulation, biopharmaceutics, and antimalarial evaluation](https://medichelpline.com/clinical-feed/pubmed-42556438.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127272](https://doi.org/10.1016%2Fj.ijpharm.2026.127272)
- **Detail Markdown URL:** [Chloroquine–resin complexes: formulation, biopharmaceutics, and antimalarial evaluation](https://medichelpline.com/clinical-feed/pubmed-42556438.md)

> **Executive GIST:** - Malaria remains a significant global health problem, particularly in children under five, and pediatric dosing often requires tablet fragmentation that increases bitterness and may reduce adherence. - The study tested whether a **chloroquine-resin complex (CLQ-R)** could mask bitterness while preserving chloroquine's pharmacokinetic profile and antimalarial efficacy. - CLQ-R was prepared at a 1:1 (w/w) drug-to-resin ratio using **polacrilin potassium (Amberlite IRP88)** as the ion-exchange resin for taste masking. - In vitro antimalarial activity was evaluated against **Plasmodium falciparum 3D7** with parasite proliferation measured by **SYBR Green** DNA staining. - Pharmacokinetic (plasma concentration) and biochemical parameters were measured after oral administration of CLQ or CLQ-R in mice. - In vivo efficacy was assessed using **Plasmodium berghei ANKA** infection in C57BL/6 mice with the four-day suppressive test and recrudescence test; parasitemia was quantified by flow cytometry. - Taste perception was measured using a 48-hour two-bottle preference test to assess palatability. - The abstract reports that **CLQ-R displayed similar plasma concentration and biochemical profiles to CLQ**, indicating preserved pharmacokinetics and no reported biochemical differences in the parameters measured. - The source text is truncated and does not report the remainder of the results, including detailed in vitro efficacy outcomes, in vivo antimalarial performance, statistical data, or specific taste-preference results; those details were not reported in the available source.

### 8. [Pilot-scale transfer and optimization of a supercritical CO2 PGSS method for producing drug-loaded](https://medichelpline.com/clinical-feed/pubmed-42551720.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127281](https://doi.org/10.1016%2Fj.ijpharm.2026.127281)
- **Detail Markdown URL:** [Pilot-scale transfer and optimization of a supercritical CO2 PGSS method for producing drug-loaded](https://medichelpline.com/clinical-feed/pubmed-42551720.md)

> **Executive GIST:** - The study reports successful transfer of a supercritical CO2-based **PGSS** (Particles from Gas-Saturated Solutions) liposome production process from laboratory to pilot scale, expanding reactor volume from 50 mL to 500 mL. - A **Quality by Design** approach with a design of experiments on a simplified soy phosphatidylcholine formulation was used to identify and optimize key process parameters for scale-up. - Optimized parameters were validated across multiple drug-encapsulating liposome formulations, demonstrating **process robustness** and transferability. - At pilot scale, the process reproducibly produced **liposomes** with mean diameters below 200 nm and polydispersity indices near 0.30. - The PGSS process was applied successfully to drug-loaded formulations, achieving **high encapsulation efficiencies** while preserving suitable physicochemical properties. - Cryo-TEM imaging confirmed consistent formation of vesicular structures in the produced formulations. - Lipid chemical stability was maintained during the process, with only minimal hydrolysis and no significant increase in oxidation, including for unsaturated lipids. - The method is described as **solvent-free** and single-step, highlighting its potential industrial relevance for scalable liposome manufacturing while maintaining critical quality attributes and formulation stability. - The paper concludes that the PGSS supercritical CO2 approach is robust, scalable, and relevant as an alternative liposome production technology for drug encapsulation. - Details on exact optimized parameter values, specific drug compounds used, and quantitative encapsulation efficiency values were not reported in the abstract and require consultation of the full text for numbers and procedural specifics.

### 9. [Low-temperature FDM 3D printing of immediate-release glipizide tablets: formulation and dose custo](https://medichelpline.com/clinical-feed/pubmed-42546995.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127275](https://doi.org/10.1016%2Fj.ijpharm.2026.127275)
- **Detail Markdown URL:** [Low-temperature FDM 3D printing of immediate-release glipizide tablets: formulation and dose custo](https://medichelpline.com/clinical-feed/pubmed-42546995.md)

> **Executive GIST:** - This study evaluated low-temperature hot-melt extrusion (HME) combined with fused deposition modeling (FDM) 3D printing to produce personalized immediate-release **glipizide (GPZ)** tablets, addressing GPZ’s low aqueous solubility and high melting point. - Filaments were prepared at 60 °C and printed at 90 °C using a polymer matrix based on **KVA64** with mannitol (MAN) and triethyl citrate (TEC) as excipients/plasticizer. - Six formulations were screened; the optimal filament composition was 12% w/w GPZ, 69% w/w KVA64, 10% w/w MAN, and 9% w/w TEC; this filament showed acceptable flexibility, feedability, and moisture resistance. - Solid-state characterization (DSC, PXRD, TGA) indicated a **partially amorphous GPZ dispersion** with residual crystalline domains and no detectable thermal degradation during processing. - A mixed-level factorial design tested effects of infill pattern, number of shells, and layer thickness on drug release at 10 minutes; after Bonferroni correction, infill pattern, number of shells, and the infill pattern × layer thickness interaction remained significant. - Generally, grid infill and fewer shells accelerated drug release; the influence of layer thickness depended on infill architecture. - Dose-adjusted tablets with 5, 7.5, 10, and 15 mg GPZ were produced by changing tablet thickness while keeping diameter constant; thinner tablets dissolved faster due to higher surface area-to-volume ratios. - The 15 mg tablet failed to meet the immediate-release dissolution criterion at 30 minutes, indicating that height-based scaling alone may not preserve immediate-release performance at higher doses. - Conclusion: Low-temperature HME-FDM can produce personalized immediate-release GPZ tablets, but both tablet geometry and internal printing architecture must be optimized across doses to maintain release performance.

### 10. [Multimodal CNN Combining UV Fluorescent Imaging and Compression Force for Tablet Dissolution Predi](https://medichelpline.com/clinical-feed/pubmed-42546994.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127276](https://doi.org/10.1016%2Fj.ijpharm.2026.127276)
- **Detail Markdown URL:** [Multimodal CNN Combining UV Fluorescent Imaging and Compression Force for Tablet Dissolution Predi](https://medichelpline.com/clinical-feed/pubmed-42546994.md)

> **Executive GIST:** - The study developed a **multimodal convolutional neural network (MI-CNN)** to predict tablet-level dissolution profiles for immediate-release tablets using UV fluorescent images and compression force as inputs. - Models compared: MI-CNN (images + compression force), SI-CNN (images only), and an MLP using hand-crafted histogram descriptors plus compression force. - Dataset was generated using a Design of Experiments covering multiple compression forces, disintegrant concentrations, and acetylsalicylic acid particle size fractions; an unseen particle size range was included to test generalization. - The MI-CNN delivered the most consistent performance with similar training and validation errors (RMSEtrain: 13.09% and RMSEval: 12.54%), indicating robust generalization across formulation conditions. - The SI-CNN (images only) had reduced validation accuracy (RMSEval: 25.41%), particularly where dissolution differences were driven by **tablet compaction**. - The MLP showed strong training fit (RMSEtrain: 2.94%) but poor validation performance (RMSEval: 27.15%), suggesting overfitting and insufficient representational power of histogram-based features for this dataset. - Explainable AI using SHapley Additive exPlanations (SHAP) indicated that both **compression force** and image-derived features contributed to model predictions. - The findings support combining process variables with image-based information for surrogate dissolution modeling and potential real-time release testing strategies. - Details such as exact model architectures, training hyperparameters, dataset size, and preprocessing steps were not reported in the abstract and are available only in the full text.

### 11. [Predictive compaction modelling for ternary direct-compression formulations](https://medichelpline.com/clinical-feed/pubmed-42546992.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127253](https://doi.org/10.1016%2Fj.ijpharm.2026.127253)
- **Detail Markdown URL:** [Predictive compaction modelling for ternary direct-compression formulations](https://medichelpline.com/clinical-feed/pubmed-42546992.md)

> **Executive GIST:** - Direct compression formulation development is resource intensive and requires characterising compressibility and compactability across formulation space. The study extended a global optimisation of mixture rules to a **ternary formulation** space (API - brittle filler - elastic filler). - Test systems used three grades each of **paracetamol** and **ibuprofen** combined with a consistent placebo base to evaluate predictive performance across APIs and grades. - Two empirical compaction/compression models were central: the **Kawakita** model for compression behaviour and the **Ryshkewitch–Duckworth** model for tensile strength (compactibility). - The global optimisation approach outperformed traditional line-of-best-fit mixture rules, achieving strong performance for the Kawakita model (R2 > 0.94; RMSE 30% across all formulations; median API savings were 75%–95% under Acceptable and Good performance thresholds. - Savings declined as performance thresholds tightened, with the highest variability seen in ibuprofen formulations. The Kawakita model enabled reductions across all thresholds; the Ryshkewitch–Duckworth model supported reductions mainly up to the Acceptable threshold. - MBDoE did not systematically outperform random experiment selection, but the optimisation framework still offers a material-sparing way to populate empirical models for predicting **tablet porosity** and **tensile strength** of ternary blends. - Conflict of interest: financial support reported from GlaxoSmithKline R&D and Scottish Funding Council for one author; other authors declared no relevant competing interests.

### 12. [pH‑sensitive hydrogel magnetic capsule microrobot (CHM) swarm for targeted drug delivery](https://medichelpline.com/clinical-feed/pubmed-42546990.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127233](https://doi.org/10.1016%2Fj.ijpharm.2026.127233)
- **Detail Markdown URL:** [pH‑sensitive hydrogel magnetic capsule microrobot (CHM) swarm for targeted drug delivery](https://medichelpline.com/clinical-feed/pubmed-42546990.md)

> **Executive GIST:** - The study reports shell-core **hydrogel magnetic capsule microrobots (CHMs)** fabricated by coaxial microfluidics for targeted drug delivery. - CHMs have tunable diameters from 100 to 600 μm and a reported saturation magnetization of 5.4 emu g⁻1. - Individual CHMs under rotating magnetic fields perform torque-driven rolling with a maximum velocity of 0.76 mm s⁻1. - Using programmable rotating gradient magnetic fields, CHM swarms reach a maximum collective velocity of 0.72 mm s⁻1. - The swarm can reversibly transform between **clustered, elongated, chain-like, and dispersed** morphologies; aggregation and dispersion efficiencies were 94% and 90% respectively within 1–8 Hz. - The control approach uses a movable magnetic gradient point to confine and transport CHMs collectively rather than relying on dipole-induced self-assembly. - CHM swarms navigated confined channels, crossed obstacles, and achieved targeted locomotion in a simulated gastrointestinal environment. - CHMs demonstrate **pH-responsive drug release**: cumulative release of 4% at pH 1.2 and 23% at pH 7.6 within 10 hours. - The authors propose this high-integrity, non-assembly swarm control strategy as a method to manipulate larger drug-loaded microrobots stably for targeted delivery. - The paper reports no competing interests declared by the authors.

### 13. [Brinzolamide solid-state determines release from hot-melt extruded PLGA intravitreal implants](https://medichelpline.com/clinical-feed/pubmed-42546989.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127278](https://doi.org/10.1016%2Fj.ijpharm.2026.127278)
- **Detail Markdown URL:** [Brinzolamide solid-state determines release from hot-melt extruded PLGA intravitreal implants](https://medichelpline.com/clinical-feed/pubmed-42546989.md)

> **Executive GIST:** - The study evaluated hot-melt extruded rod-shaped intravitreal (IVT) implants (0.2 × 20 mm) made from four **PLGA** polymers with differing lactide content and molecular weight, and one **PLA** polymer. - **Brinzolamide (BRZ)** served as a model drug; its melting point (130°C) allowed production of implants where the drug was either **amorphous** (Textrusion > Tm) or **crystalline** (Textrusion < Tm). - Implants were characterized for impurities, endotoxin levels, solid-state properties, and microstructure prior to release testing. - Drug release was assessed using an in vitro model with separate artificial vitreous and saline compartments; in vitro results were combined with in silico simulations to guide implant selection and in vivo dosing. - IVT elimination of BRZ solution in rabbits (n = 12) occurred predominantly via the posterior route, with an aqueous humor/vitreous humor (AH/VH) AUC ratio of 0.0053. - Two selected amorphous implants were dosed intravitreally via trocar into rabbits (n = 8 per implant). BRZ release was sustained for 42 days both in vitro and in vivo, with AH concentrations remaining below 1% of VH levels. - **Crystalline** drug-containing implants produced a porous, non-uniform microstructure and showed faster, dissolution-driven release. - **Amorphous** drug-containing implants formed a homogeneous matrix and showed slower, PLGA degradation-limited release. - The in vitro model demonstrated good in vitro–in vivo correlation (IVIVC) for the implants tested. - The study concludes that drug solid-state critically influences implant microstructure and the dominant release mechanism in PLGA-based IVT systems, with implications for formulation design and translation for sustained ocular drug delivery.

### 14. [Mixing method effects on ritonavir/PVPVA amorphous solid dispersions made by vacuum compression mo](https://medichelpline.com/clinical-feed/pubmed-42546988.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127280](https://doi.org/10.1016%2Fj.ijpharm.2026.127280)
- **Detail Markdown URL:** [Mixing method effects on ritonavir/PVPVA amorphous solid dispersions made by vacuum compression mo](https://medichelpline.com/clinical-feed/pubmed-42546988.md)

> **Executive GIST:** - This study compared two powder mixing approaches—**physical blending (PB)** and **cryo-milling (CM)**—prior to fabrication of amorphous solid dispersions (ASDs) via **vacuum compression molding (VCM)**, using ritonavir (RTV) and poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA). - VCM is a melting-based molding approach that lacks intrinsic mixing during processing, while melt-based methods such as hot-melt extrusion provide effective mixing during melt processing. - Cryo-milling is commonly applied before VCM to improve powder mixing, but the particle size or characteristics required to achieve homogeneous, single-phase ASDs were previously unclear. - The study produced ASD discs with drug loadings (DLs) ranging from low to high (5–50% DL) and evaluated solid-state properties and dissolution performance using a microscope-enabled disc dissolution system (MeDDiS). - Bulk-level mixing assessments (ATR-FTIR and pigment tests) suggested similar overall mixing uniformity for PB and CM powders, but dissolution performance diverged between the two methods. - CM discs exhibited a marked change in dissolution behavior—a distinct “cliff” in performance—near an intermediate DL (~30% DL), indicating a threshold effect on release. - PB discs generally showed inferior dissolution, with progressively reduced drug release as DL increased, implying localized heterogeneity affecting performance. - ATR-FTIR mapping indicated PB samples contained localized amorphous drug-rich domains, whereas CM promoted a more uniform dispersion of drug within polymer at the microstructural level. - The authors concluded that ASD performance after VCM depended not only on apparent powder mixing but also on the degree of microstructural fusion achieved during molding, which in turn depends on the spatial proximity of drug and polymer in the pre-VCM powder. - Overall, effective pre-molding processing that enhances intimate contact between drug and polymer appears critical to achieving desirable **dissolution** and single-phase **ASD** performance when using **VCM**.

### 15. [Paclitaxel-loaded spermidine‑geranic acid ionic liquid nanoaggregates for enhanced uptake and anti](https://medichelpline.com/clinical-feed/pubmed-42542261.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127257](https://doi.org/10.1016%2Fj.ijpharm.2026.127257)
- **Detail Markdown URL:** [Paclitaxel-loaded spermidine‑geranic acid ionic liquid nanoaggregates for enhanced uptake and anti](https://medichelpline.com/clinical-feed/pubmed-42542261.md)

> **Executive GIST:** - The study reports a **self-assembled nanoaggregate** system using a novel spermidine‑geranic acid ionic liquid ([Spd][Ger] IL) as a carrier for paclitaxel (PTX), aimed at addressing PTX’s poor solubility and systemic toxicity. - The synthesized [Spd][Ger] ionic liquid has a low apparent critical aggregation concentration of 0.33 mg/mL and spontaneously self-assembles in water according to molecular dynamics simulation. - PTX was efficiently encapsulated into the nanoaggregates with an **encapsulation efficiency** of 89.6% and **drug loading** of 8.3%; average particle size was 171.8 nm. - The PTX@[Spd][Ger] formulation exhibited **sustained and pH-responsive release**, with 73.66% cumulative PTX release at pH 6.5 and 61.60% at pH 7.4 over 72 hours. - In vitro cytotoxicity improved: PTX@[Spd][Ger] reduced IC50 in MCF-7 cells from 2.25 to 0.60 μg/mL and in 4T1 cells from 4.33 to 1.24 μg/mL after 24 hours, attributed to increased cellular uptake of the nanoaggregates. - In a 4T1 orthotopic mouse model, PTX@[Spd][Ger] achieved tumor suppression comparable to Taxol® with better systemic tolerability. - Authors conclude that **[Spd][Ger]-based nanoaggregates** represent an effective and potentially safer platform for delivery of water‑insoluble drugs such as paclitaxel. - The abstract does not report full experimental protocols, detailed safety/toxicity metrics, long‑term in vivo outcomes, or scale‑up/manufacturing details; those details are not reported in the source abstract.

### 16. [In vitro antrum model to evaluate gastroretentive dosage forms under physiologic peristalsis](https://medichelpline.com/clinical-feed/pubmed-42542260.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127252](https://doi.org/10.1016%2Fj.ijpharm.2026.127252)
- **Detail Markdown URL:** [In vitro antrum model to evaluate gastroretentive dosage forms under physiologic peristalsis](https://medichelpline.com/clinical-feed/pubmed-42542260.md)

> **Executive GIST:** - Gastroretentive drug delivery systems aim to prolong gastric residence time but show inconsistent in vivo performance, partly because current in vitro models underrepresent the mechanical role of **antral peristalsis** in gastric emptying. - The authors developed a next-generation mechanical in vitro **antrum model** that reproduces mechanically relevant conditions controlling gastric emptying. - The system uses a flexible tubular compartment with mechanically induced peristaltic waves and allows controlled variation of key parameters: **wave velocity** (3 mm/s), **fluid volume** (50–150 mL), **inclination** (0–40°), and **occlusion as residual lumen diameter** (1.6–25.6 mm). - Test objects with defined differences in size, density, and deformability were used to probe transport behavior under the modeled peristaltic conditions. - Results showed transport is governed principally by the interaction of **geometric confinement, deformation, and contact mechanics** rather than single parameters alone. - Rigid objects were expelled once a critical lumen diameter threshold was reached; highly deformable or entangled structures partially resisted peristaltic transport. - Observed size-dependent transport patterns aligned with in vivo findings previously reported in the literature. - The model is presented as a simple, mechanistically relevant platform for early-stage **screening** of gastroretentive dosage forms and supports a mechanics-driven understanding of gastroretention. - The authors declared no competing financial interests or personal relationships that could have influenced the reported work.

### 17. [Microspheres for Myocardial Infarction Therapy: Design, Delivery, and Applications](https://medichelpline.com/clinical-feed/pubmed-42542259.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127262](https://doi.org/10.1016%2Fj.ijpharm.2026.127262)
- **Detail Markdown URL:** [Microspheres for Myocardial Infarction Therapy: Design, Delivery, and Applications](https://medichelpline.com/clinical-feed/pubmed-42542259.md)

> **Executive GIST:** - Myocardial infarction (MI) causes long-term adverse remodeling and remains a leading cause of heart failure despite improved early survival with current interventions. - **Microspheres** are injectable, tunable particulate platforms with high surface-to-volume ratio and have clinical uses in chemotherapy, hemostasis, and long-acting injectables. - In MI therapy, microspheres can encapsulate a variety of **bioactive agents**, modulate the infarct microenvironment, and support cardiac repair via minimally invasive delivery. - Key microsphere design variables include **morphology**, particle **size**, material composition, and surface functionalization, all of which affect payload release and tissue interactions. - Major fabrication techniques covered are **emulsion–solvent evaporation**, **spray drying**, **electrospraying**, and **microfluidics**, each offering different control over size, uniformity, and drug loading. - Delivery routes for cardiac applications include **intramyocardial**, **epicardial**, and **intracoronary** administration; route selection influences localization, retention, and invasiveness. - Microspheres have been investigated for direct delivery of growth factors, cytokines, small molecules, and for supporting **cell therapy** and three-dimensional engineered cardiac tissues. - Design strategies emphasize controlled release, microenvironment modulation, and functionalization to improve targeting and therapeutic efficacy. - The review summarizes preclinical evidence but notes translational hurdles; limitations and future perspectives are discussed to guide innovation and clinical translation. - Keywords and thematic focuses include **bioactive-agent delivery**, **functionalization strategies**, **microspheres**, **myocardial infarction**, and **tissue engineering**.

### 18. [Microneedle-mediated ocular drug delivery: overcoming barriers from drops to devices](https://medichelpline.com/clinical-feed/pubmed-42542258.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127260](https://doi.org/10.1016%2Fj.ijpharm.2026.127260)
- **Detail Markdown URL:** [Microneedle-mediated ocular drug delivery: overcoming barriers from drops to devices](https://medichelpline.com/clinical-feed/pubmed-42542258.md)

> **Executive GIST:** - Ocular disease treatment is limited by anatomical and physiological barriers that reduce drug penetration and bioavailability, making many conventional approaches suboptimal. - Traditional delivery methods—**eye drops**, systemic therapy, and intravitreal injections—show shortcomings such as poor bioavailability, rapid precorneal clearance, frequent dosing, invasiveness, and limited patient adherence. - **Microneedle (MN)**-mediated ocular drug delivery is presented as a minimally invasive strategy to enable localized, targeted, and sustained delivery to anterior and posterior eye segments. - The review outlines key microneedle design principles, material selection, and fabrication techniques, emphasizing that material choice should align with the intended ocular tissue target. - Multiple administration routes for ocular MNs are discussed: **corneal**, **trans-scleral**, **subconjunctival**, and **suprachoroidal** delivery, with integration of routes to disease-specific applications. - The article compares microneedle-based systems with conventional ocular delivery approaches, highlighting potential improvements in ocular bioavailability and reduced treatment burden. - Advances in smart and stimuli-responsive microneedles are summarized, indicating a trend toward responsive or controlled release platforms (details on specific mechanisms were not reported in the abstract). - The review addresses translational challenges and practical considerations including manufacturing scale-up, sterilization, regulatory aspects, and steps needed for clinical translation. - The authors conclude that ocular microneedles represent a promising next-generation platform to enhance therapeutic outcomes, patient compliance, and accelerate clinical translation across diverse ocular disorders. - Conflict of interest: authors declared no known competing financial interests or personal relationships influencing the work.

### 19. [Atorvastatin-loaded frankincense SNEDDS thermoresponsive hydrogel improves wound healing in a rat](https://medichelpline.com/clinical-feed/pubmed-42542257.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127264](https://doi.org/10.1016%2Fj.ijpharm.2026.127264)
- **Detail Markdown URL:** [Atorvastatin-loaded frankincense SNEDDS thermoresponsive hydrogel improves wound healing in a rat](https://medichelpline.com/clinical-feed/pubmed-42542257.md)

> **Executive GIST:** - The study repurposed the antihyperlipidemic drug **atorvastatin** for topical wound healing by incorporating it into a frankincense oil–based **self-nanoemulsifying drug delivery system (SNEDDS)**, then embedding that SNEDDS into a **thermosensitive poloxamer hydrogel**. - SNEDDS formulations used frankincense (FRK) oil, Tween® 20, and PEG 400; they were evaluated for thermodynamic stability, emulsification efficiency, droplet size, cloud point, and drug content. - The optimized SNEDDS showed nanometric droplet size, high drug content, and good physical stability and was mixed into the poloxamer gel using the cold method. - The resulting ATR-SNEDDS hydrogel demonstrated improved spreadability, appropriate rheological behavior, and complete drug release within 6 hours in the reported in vitro evaluation. - In a rat incisional wound model, topical ATR-SNEDDS hydrogel significantly increased wound contraction compared with the diseased control and with a marketed standard (reported as 40% vs. diseased group; 16% vs. marketed standard). - Treatment with ATR-SNEDDS hydrogel markedly reduced oxidative stress and inflammatory biomarkers: malondialdehyde (MDA) decreased by 68% and TNF-α decreased by 60% compared with controls reported in the source. - Antioxidant defenses were increased: superoxide dismutase (SOD) rose by 48% and reduced glutathione (GSH) rose by 50% in treated animals as reported. - Histopathological and immunohistochemical analyses showed accelerated re-epithelialization, greater collagen deposition, and reduced inflammatory cell infiltration in wounds treated with the ATR-SNEDDS hydrogel. - Authors conclude the **ATR-SNEDDS thermosensitive hydrogel** provides a synergistic delivery platform that enhances topical atorvastatin performance and shows promising acute wound-healing potential in an animal model. - Specific experimental details such as exact concentrations, animal numbers, dosing regimen, and statistical analyses were not reported in the PubMed abstract and therefore are not available here.

### 20. [Chitosan-based hydrogels for intranasal drug delivery in brain disease treatment](https://medichelpline.com/clinical-feed/pubmed-42537824.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127259](https://doi.org/10.1016%2Fj.ijpharm.2026.127259)
- **Detail Markdown URL:** [Chitosan-based hydrogels for intranasal drug delivery in brain disease treatment](https://medichelpline.com/clinical-feed/pubmed-42537824.md)

> **Executive GIST:** - Neurodegenerative and other brain diseases pose increasing public health challenges because effective delivery of therapeutics to the central nervous system (CNS) is limited by the **blood-brain barrier (BBB)**. - Noninvasive strategies such as **intranasal (IN)** administration and nanoscale delivery systems are under active investigation to improve brain targeting and patient acceptability. - IN administration enables direct nose-to-brain transport mainly via the **olfactory pathway**, with the trigeminal route as an additional conduit. - **Chitosan (CS)-based hydrogels** have attracted attention for IN delivery due to **biocompatibility**, **biodegradability**, and **mucoadhesive** properties that prolong nasal residence time. - CS hydrogels can transiently modulate epithelial tight junctions and enhance drug permeation across nasal epithelium, supporting improved CNS uptake. - Recent work summarized in the review examines CS-based IN hydrogels applied to multiple brain conditions: **Alzheimer’s disease (AD)**, **Parkinson’s disease (PD)**, depressive disorders, ischemia, brain tumors, epilepsy and seizures, and schizophrenia. - The review analyzes relationships between **hydrogel design** (formulation attributes) and therapeutic performance in preclinical settings, emphasizing how material properties influence residence time, permeation, and drug release. - Translational challenges identified include moving formulations from bench to bedside, regulatory and clinical development hurdles, and the need for standardized evaluation metrics; the review outlines future perspectives for clinical development of CS-based IN hydrogel systems. - The authors declare no competing financial interests or personal relationships that influenced the work.

### 21. [Solid-form impurity increases punch sticking risk in carbamazepine tablets](https://medichelpline.com/clinical-feed/pubmed-42532320.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127245](https://doi.org/10.1016%2Fj.ijpharm.2026.127245)
- **Detail Markdown URL:** [Solid-form impurity increases punch sticking risk in carbamazepine tablets](https://medichelpline.com/clinical-feed/pubmed-42532320.md)

> **Executive GIST:** - The study examined how **solid-form impurity** influences **punch sticking** during tablet manufacture using two carbamazepine batches (CBZ-A and CBZ-B) from different suppliers. - CBZ-A was exclusively carbamazepine **form III**; CBZ-B contained a mixture of form III and **carbamazepine dihydrate (CBZd)**. - CBZ-B showed a substantially greater tendency to stick to punches than CBZ-A, implicating the presence of the hydrate impurity in increased sticking propensity. - A design of experiments (DOE) using CBZd investigated the effects of **particle size**, **compaction pressure**, and **API loading** on sticking mass. - Results from the DOE indicated that **smaller particle size**, **lower compaction pressure**, and **higher API loading** each increased punch sticking. - A significant interaction between particle size and API loading was identified, meaning those two variables jointly modulate sticking behavior. - The authors conclude that controlling **solid-state phase purity** of the API, together with particle size, API loading, and compaction pressure, is important for robust tablet manufacturing. - The abstract does not report detailed quantitative results, exact experimental conditions, or numerical values for sticking mass; those details are available in the full text source. - Keywords reported: Carbamazepine; Design of experiments; Hydrate; Particle size; Punch sticking.

### 22. [Clobetasol-loaded core-active lipid nanoparticles for inflammatory skin conditions](https://medichelpline.com/clinical-feed/pubmed-42526729.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/j.ijpharm.2026.127254](https://doi.org/10.1016%2Fj.ijpharm.2026.127254)
- **Detail Markdown URL:** [Clobetasol-loaded core-active lipid nanoparticles for inflammatory skin conditions](https://medichelpline.com/clinical-feed/pubmed-42526729.md)

> **Executive GIST:** - The article titled **Clobetasol-loaded core-active lipid nanoparticles: an enhanced therapy for inflammatory skin conditions** was published in International Journal of Pharmaceutics (Int J Pharm) and is available as a free article on PubMed (PMID 42526729, DOI 10.1016/j.ijpharm.2026.127254). - The paper lists multiple authors from the University of Barcelona and Hospital Universitari de Bellvitge, including J Madariaga-Burgos and colleagues, with affiliations to the Department of Pharmacy and Pharmaceutical Technology and the Institute of Nanoscience and Nanotechnology (IN2UB), and to departments at Bellvitge Institute for Biomedical Research. - Publication details shown: Epub 2026 Jul 29; journal issue . 2026 Sep 5:702:127254. The PubMed entry is a free article. - The title and the partial abstract indicate the work concerns **Clobetasol propionate (CP)**, described as a **high-potency corticosteroid** used to treat **inflammatory skin conditions**, and the development or evaluation of CP formulated in **core-active lipid nanoparticles** to enhance therapy. - The PubMed page provides bibliographic metadata and full-text links but the abstract in the provided source text is truncated; methods, experimental results, safety data, formulation details, and conclusions are not present in the excerpt. - Affiliations show interdisciplinary collaboration between pharmaceutical formulation groups (University of Barcelona) and clinical/research groups in pathology, immunology, and experimental therapy (Bellvitge), suggesting the study spans formulation science and biological evaluation, though specific experiments and outcomes are not reported in the source text. - Contact information for corresponding authors is partially indicated in affiliations; electronic addresses for J Manils and E Sánchez-López are listed on the PubMed entry. - The PubMed entry includes navigation links to full text at Elsevier and other full-text options; however, the excerpt here does not include the full abstract or full-text content. - Because the source excerpt is incomplete, specific numerical findings, study design, statistical analyses, adverse events, and clinical recommendations were not reported in the provided text.

### 23. [Widening medication adherence gap: impact on modern therapeutics and system solutions](https://medichelpline.com/clinical-feed/plos-medicine-0-the-widening-medication-adherence-gap.md)
- **Source:** PLOS Medicine | **Published:** 2026-09-04
- **Detail Markdown URL:** [Widening medication adherence gap: impact on modern therapeutics and system solutions](https://medichelpline.com/clinical-feed/plos-medicine-0-the-widening-medication-adherence-gap.md)

> **Executive GIST:** - The gap between drug efficacy in trials and real-world effectiveness is growing, largely because of **medication nonadherence**, which causes substantial opportunity costs as modern therapies become more potent. - Contemporary therapeutics with larger treatment effects (for example, semaglutide, direct oral anticoagulants, and recombinant zoster vaccine) are not delivering full benefits in practice when patients discontinue or underuse them. - Real-world data show that 20%–50% of patients discontinue **GLP-1 RAs** within the first year, many use lower doses than in trials, and weight-loss outcomes in practice are consistently less than trial results; highly adherent patients approach trial outcomes. - For GLP-1 RAs prescribed for cardiorenal or kidney protection, discontinuation forfeits ongoing reductions in morbidity and mortality because benefits depend on continued exposure rather than durable protection after withdrawal. - A meta-analysis of nearly 595,000 patients with atrial fibrillation found only two-thirds maintained good adherence to **direct oral anticoagulants**, and nonadherence was associated with a 39% increased stroke risk, illustrating measurable harms from nonadherence. - Completion of the two-dose **recombinant zoster vaccine (RZV)** series was 72% overall in a US study of more than 726,000 adults, with lower completion among racial/ethnic minorities, younger adults, and lower-income households; emerging studies link complete RZV dosing with reduced dementia risk. - The core problem is stable adherence rates amid progressively more effective treatments: as treatment effects grow, the benefit forgone through nonadherence grows proportionally. - Nonadherence is heterogeneous (cost-related gaps, unintentional lapses); not all discontinuation is inappropriate—some represents shared decision-making after adverse effects. - Established individual-level interventions (education, simpler dosing, communication) remain necessary but are often insufficient; a Cochrane review of 182 randomized trials found only modest adherence or outcome gains from such bundles. - System-level solutions are needed: redesigning coverage and funding, pharmacist-led management (collaborative practice agreements, transition programs), value-based insurance design, EHR-integrated completion tracking for multi-dose vaccines, and addressing structural barriers like cost, insurance coverage, and supply. - A randomized trial eliminating copayments after myocardial infarction improved adherence by 4%–6% and reduced first major vascular events without increasing total health spending, illustrating the potential of system-level change. - Detecting nonadherence in routine practice is challenging; clinicians underestimate it and current measures (refill records, self-report, EHR notes) capture partial information; AI may help but rigorous evidence that it improves clinical endpoints is limited. - To realize the full value of modern therapeutics we must invest in system-level interventions and implementation research as rigorously as we invest in drug discovery.

### 24. [MEL-Steered PharmacoNet: Adapting DL Prescreening to Synthon-Based Docking for Target-Specific Vir](https://medichelpline.com/clinical-feed/biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-04
- **Detail Markdown URL:** [MEL-Steered PharmacoNet: Adapting DL Prescreening to Synthon-Based Docking for Target-Specific Vir](https://medichelpline.com/clinical-feed/biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting.md)

> **Executive GIST:** - The preprint presents a method to adapt a general-purpose deep-learning pharmacophore prescreener, **PharmacoNet**, to individual protein targets using data already produced during V-SYNTHES-style fragment docking. - V-SYNTHES (Virtual SYNthon Hierarchical Enumeration Screening) docks a Minimal Enumeration Library (**MEL**) of fragments to a pocket, then expands top fragments into full ligands for large-scale docking; only a small fraction of similarly well-scoring fragments are expanded under fixed docking budgets. - General prescreeners can reallocate docking budget by scoring full-ligand proxies, but existing tools do not account for **target-specific** pocket preferences. - The authors propose MEL-Steered PharmacoNet, a parameter-efficient adaptation framework that specializes PharmacoNet to a given target through two mechanisms: empirical density-map steering of predicted pharmacophore hotspots, and empirical fine-tuning of interaction-type scoring weights. - The approach leverages fragment-docking signals (which hotspots and interaction types a pocket favors) to adjust PharmacoNet without additional experimental data or full model retraining. - MEL-Steered PharmacoNet was evaluated on three structurally distinct GPCR targets (CB2, GPR91, 5-HT2AR) and yielded substantial gains in enrichment factor at 100 (EF100) compared with a random baseline and with generic PharmacoNet. - Reported EF100 improvements of MEL-Steered PharmacoNet over PharmacoNet were 8.94x for CB2, 6.87x for GPR91, and 1.69x for 5-HT2AR. - The fitted per-target interaction weights provided chemically interpretable interaction profiles that differ from PharmacoNet's generic fixed weights, indicating pocket-specific interaction preferences recoverable from fragment docking. - The method preserves the ultra-fast screening capability of PharmacoNet while improving target-specific performance and makes use only of fragment-docking data already generated in the V-SYNTHES pipeline.

### 25. [Esketamine vs Sufentanil for Quality of Recovery After Outpatient Gynecological Surgery](https://medichelpline.com/clinical-feed/pubmed-42693883.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1080/07853890.2026.2723715](https://doi.org/10.1080%2F07853890.2026.2723715)
- **Detail Markdown URL:** [Esketamine vs Sufentanil for Quality of Recovery After Outpatient Gynecological Surgery](https://medichelpline.com/clinical-feed/pubmed-42693883.md)

> **Executive GIST:** - This randomized, double-blind clinical trial compared **esketamine** (0.2 mg/kg) with **sufentanil** (0.1 μg/kg), each combined with **propofol** (1.5–3 mg/kg), for sedation in outpatient gynecological procedures. - 126 patients were randomized; 125 were analyzed (62 esketamine, 63 sufentanil) after one patient lacked follow-up data. - The primary endpoint was quality of recovery measured by the **QoR-15** score on postoperative day (POD) 1. - Mean QoR-15 on POD1 was 137.9 (SD 14.5) in the esketamine group and 137.8 (SD 10.7) in the sufentanil group; no significant difference (absolute difference 0.2; 95% CI −4.2 to 4.6; p = 0.93). - Secondary outcomes included QoR on POD2, sedation success, PACU length of stay, injection pain, postoperative pain, nausea/vomiting, fatigue, satisfaction, sleep quality, anxiety and depression. - Esketamine group had longer median PACU stay (28.0 vs 23.0 minutes; p < 0.001) and lower incidence of severe injection pain (22.6% vs 50.8%; p = 0.002). - At 30 minutes postoperatively, more esketamine patients had pain scores ≥ 4 (30.6% vs 6.3%; p = 0.001) and reported higher fatigue (median 3.0 vs 2.0; p = 0.01). - Other secondary outcomes, such as nausea/vomiting, sedation success, patient and clinician satisfaction, sleep quality, and anxiety/depression, did not differ significantly between groups. - Trial registration: Chinese Clinical Trial Registry ChiCTR2500098466. No additional details beyond the abstract were provided in the source.

### 26. [Role-Play Verbal De-Escalation Simulation for Nursing Students: Qualitative Outcomes](https://medichelpline.com/clinical-feed/pubmed-42691297.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1097/CNJ.0000000000001410](https://doi.org/10.1097%2FCNJ.0000000000001410)
- **Detail Markdown URL:** [Role-Play Verbal De-Escalation Simulation for Nursing Students: Qualitative Outcomes](https://medichelpline.com/clinical-feed/pubmed-42691297.md)

> **Executive GIST:** - This qualitative study evaluated a **role-play verbal de-escalation** simulation designed for Associate of Science degree **nursing students**. The training used simulation patients rather than high-fidelity mannequins. - A three-step training process was implemented to teach verbal de-escalation techniques; the source reports the process but does not detail each step in the abstract. - Data collection included participant surveys and structured debriefing; analysis used qualitative methods to interpret responses and themes. - Student-reported outcomes included increased **critical thinking** and greater clinical preparedness for interactions with real patients after participating in the simulations. - Participants also reported an improved understanding of relevant **pathophysiology**, suggesting integration of clinical reasoning with communication skills. - The simulation experience enhanced student awareness and use of **safety techniques** to manage stressful patient situations. - The study positions role-play simulation with live simulation patients as a viable educational method for teaching de-escalation compared with use of mannequins. - Keywords associated with the study are behavioral health, de-escalation, nursing, nursing students, qualitative research, role-play, and simulation. - MeSH terms listed include Clinical Competence, Patient Simulation, Role Playing, Simulation Training/methods, Students, Nursing/psychology, and Qualitative Research, indicating the study’s focus on competence development and educational methods. - The article appears in J Christ Nurs (2026 Oct–Dec), with DOI 10.1097/CNJ.0000000000001410 and PMID 42691297. The abstract does not report quantitative measures, specific curricula content, participant numbers, or detailed analytic procedures beyond qualitative analysis.

### 27. [Subjective Oral Status, Oral Health Behaviours, and History of Systemic Disease in Older Adults](https://medichelpline.com/clinical-feed/pubmed-42694012.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.3290/j.ohpd.c_2807](https://doi.org/10.3290%2Fj.ohpd.c_2807)
- **Detail Markdown URL:** [Subjective Oral Status, Oral Health Behaviours, and History of Systemic Disease in Older Adults](https://medichelpline.com/clinical-feed/pubmed-42694012.md)

> **Executive GIST:** - This cross-sectional analysis used data from 979 community-dwelling older adults aged 65–85 in Higashiura-cho, Aichi Prefecture, collected in 2018 via group examination and self-administered questionnaire. - Investigators examined associations between history of systemic diseases (including cancer, myocardial infarction, stroke, hypertension, diabetes, liver disease, lung disease, mental illness, and bone disease) and oral-related variables: **concerns about teeth and mouth condition**, **use of interdental brushes and dental floss**, and **experience of oral hygiene instruction**. - Multivariable logistic regression models were used to test associations between oral variables and systemic disease histories. - Average participant age was 73.0 ± 5.2 years; 52.4% were female. - No significant associations were found between having **concerns about teeth and mouth condition** or using **interdental brushes and dental floss** and any systemic disease history examined. - Receiving **oral hygiene instruction** was positively associated with a history of **hypertension** (odds ratio 1.4; 95% confidence interval 1.0–2.0). - Authors caution that all disease and oral-health measures were self-reported; this limits causal inference and may introduce reporting bias. - The study suggests dental hygienists should consider patients’ systemic disease status—particularly **hypertension**—when providing oral hygiene instruction, but findings should be interpreted cautiously due to study design and self-reporting.

### 28. [Genomic, Transcriptomic, and Epidemiologic Evidence Linking Diabetic Retinopathy to Alzheimer Dise](https://medichelpline.com/clinical-feed/pubmed-42693903.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.7189/jogh.16.04311](https://doi.org/10.7189%2Fjogh.16.04311)
- **Detail Markdown URL:** [Genomic, Transcriptomic, and Epidemiologic Evidence Linking Diabetic Retinopathy to Alzheimer Dise](https://medichelpline.com/clinical-feed/pubmed-42693903.md)

> **Executive GIST:** - The study investigated whether **diabetic retinopathy (DR)** and **Alzheimer disease (AD)** share genetic susceptibility, expression-mediated associations, cellular features, and convergent biological pathways using multi-omics and population data. - A two-sample **Mendelian randomisation (MR)** assessed the association between genetically predicted liability to DR and AD risk, finding a modest positive association. - **Bayesian colocalisation** analysis supported at least one shared genetic signal between DR and AD loci. - Summary-data-based MR (SMR) detected three genes with shared expression-mediated associations across DR and AD. - Single-cell RNA sequencing analyses identified overlapping cellular features and implicated neurovascular and metabolic pathways in both conditions. - An MR-based mediation analysis tested whether lipid-related, metabolic, or inflammatory traits mediated the DR–AD association and found no significant mediators among the traits assessed. - A longitudinal analysis in the UK Biobank cohort produced findings directionally consistent with the genetic analyses, supporting an observational association between DR and incident AD. - Overall interpretation: genetic liability to **DR** is linked to increased **AD** risk, accompanied by shared expression-mediated effects and convergent neurovascular–metabolic pathways, suggesting DR could be a clinically accessible marker of neurodegenerative vulnerability. - Conflict of interest: authors reported no relevant interests on ICMJE disclosure forms.

### 29. [Depression plus Diabetes: Increased Mortality and Complication Risks — Systematic Review and Meta-](https://medichelpline.com/clinical-feed/pubmed-42693777.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1017/S2045796026100882](https://doi.org/10.1017%2FS2045796026100882)
- **Detail Markdown URL:** [Depression plus Diabetes: Increased Mortality and Complication Risks — Systematic Review and Meta-](https://medichelpline.com/clinical-feed/pubmed-42693777.md)

> **Executive GIST:** - This systematic review and meta-analysis pooled data from 26 studies across nine geographic regions to compare outcomes in people with **depressive disorder and co-occurring diabetes** (depression-diabetes) versus those with diabetes only. - Literature searches covered Embase, MEDLINE, PsycInfo and Web of Science from inception to 20 December 2024; the review was registered on PROSPERO (CRD42024595145). - The depression-diabetes group had higher all-cause mortality (RR 1.30; 95% CI 1.21–1.39) and higher cardiovascular disease (CVD) specific mortality (RR 1.15; 95% CI 1.02–1.29) compared with diabetes-only patients. - Overall risk of diabetes-related complications was elevated in the depression-diabetes group (RR 1.28; 95% CI 1.18–1.40), with particularly increased risks for **metabolic complications** (RR 1.63; 95% CI 1.33–1.99) and **cardiovascular complications** (RR 1.20; 95% CI 1.11–1.29). - The depression-diabetes group had a lower pooled likelihood of retinopathy (RR 0.84; 95% CI 0.76–0.94) and comparable pooled rates for cerebrovascular complications (RR 1.36; 95% CI 0.99–1.87), nephropathy (RR 1.09; 95% CI 0.93–1.27) and peripheral vascular complications (RR 0.97; 95% CI 0.79–1.18). - Elevated mortality and complication risks were observed across regions and persisted over time, though study heterogeneity remained and stratified analyses did not fully explain between-study differences. - The authors note that prior studies were limited by depression ascertainment methods (self-report surveys) that may misclassify subclinical symptoms; this meta-analysis focused on studies comparing clinically identified depressive disorder versus diabetes-only groups. - The findings suggest poorer glycaemic control and greater physical morbidity in patients with co-occurring depression and diabetes and support comprehensive, individualized interventions to reduce avoidable complications and premature mortality in this vulnerable group.

### 30. [Rapid Ventricular Overdrive Pacing for Left Atrial Thrombectomy Without Aortic Cross-Clamping](https://medichelpline.com/clinical-feed/pubmed-42693620.md)
- **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.12659/AJCR.953416](https://doi.org/10.12659%2FAJCR.953416)
- **Detail Markdown URL:** [Rapid Ventricular Overdrive Pacing for Left Atrial Thrombectomy Without Aortic Cross-Clamping](https://medichelpline.com/clinical-feed/pubmed-42693620.md)

> **Executive GIST:** - A 73-year-old woman with a prior valve replacement presented with elevated C-reactive protein and was found on CT coronary angiography to have a large, non-mobile **left atrial** mass that persisted despite anticoagulation. - High adhesion around the aortic root made repeat median sternotomy and **aortic cross-clamping** hazardous in this reoperative case. - Thrombectomy during perfused ventricular fibrillation was considered but carries risks including coagulopathy, arrhythmia, hyperglycemia, and electrolyte disturbances that could increase overall perioperative risk. - The team selected **rapid ventricular overdrive pacing** to induce a temporary circulatory arrest while maintaining **cardiopulmonary bypass**, combined with a mini-thoracotomy approach to provide exposure and allow thrombectomy without aortic cross-clamping. - **Rapid ventricular overdrive pacing** was successfully maintained throughout the procedure, the patient was weaned from **cardiopulmonary bypass** without difficulty, extubated in the operating room, and recovered without reported complications, being discharged ambulatory. - The authors propose that temporary circulatory arrest via **rapid ventricular overdrive pacing** could be an alternative strategy for high-risk reoperative cardiovascular cases where aortic cross-clamping is hazardous. - This report is a single case; detailed procedural parameters, pacing settings, and long-term follow-up beyond discharge were not reported in the abstract.

## Machine-Readable Pagination & Traversal
- [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md)
- [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/pharmacology.md?page=2)
## Other Clinical Specialties
- [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md)
- [Public Health](https://medichelpline.com/clinical-feed/public-health.md)
- [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md)
- [Research & Trials](https://medichelpline.com/clinical-feed/research.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.